The Swedish biotech company WntResearch will present their clinical Phase I-study results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov 6.
The WntResearch drug candidate Foxy-5 has emerged as a possible new blockbuster in a novel cancer treatment concept targeting the lethal metastatic process by agonising the Wnt-5a signalling pathway in breast, colon and prostate cancer. There are at least 36 scientific studies supporting Foxy-5/Wnt-5a in these cancer forms.
Metastasis is now responsible for around 90 % of the deaths in cancer but there are no available drugs now in the market focusing on preventing metastasis. Foxy-5 may be the first.
The Phase I results will include several different biomarkers for antimetastatic effect and possibly two biomarkers for anticancerstemcell effect in breast, colon and prostate cancer. Circulating tumor cells, which are an indication of metastatic disease, in the blood have also been measured before and after treatment with Foxy-5.
I and my PdD wife have analyzed the scientific studies concerning Wnt-5a and the Wnt-5a-mimicking small molecule hexapeptide Foxy-5 carefully and found them very very promising indicating a paradigm shift in the treatment of metastatic cancer to become likely within a few years.
The internal and external preclinical work are very impressing in vitro, in vivo and importantly with clinical favorably survival data connected to high Wnt-5a expression in the primary tumors of breast, colon and prostate cancers.
Both Wnt-5a and its (and Foxy-5's) receptor Frizzled-5 are highly conserved between mice and cancer patients, reducing the risk for failure.
No side effects have been reported to the market in the as of September terminated Phase I study. Normally Wnt-5a probably has its most fundamental significance on the embryonal level.
We who have followed WntResearch closely the last few years are also "calmed" by our CEO who is a professor and very experienced cancer researcher and who has made many statements and clues for at least half a year that cannot be interpreted as negative, rather quite the opposite...
The WNT.ST stock may explode the next month when the results of the biomarkers become official.
My fundamentally based valuation now of WntResearch is an incredible over 20 times the current stock price on the Swedish small "Aktietorget" market. Aktietorget has probably several bad stocks, but at least one likely gem. Aktietorget is connected to NASDAQ OMX Stockholm.
The WntResearch market value is around USD 100 million, but a takeover could occur at some 20-40 times that figure considering the Phase I breast cancer oriented Seragon buyout by Roche in 2014.
I have made a rather short english version of the very, very long swedish analysis of WntResearch, which can be reached by this link : infoom.se
WntResearch's own official presentation of the Foxy-5 project can be found here :
wntresearch.com
To analyze WntResearch should be of great value to biotech investors seeking an extremely attractive risk/reward in my opinion. |
